Vir Biotechnology, Inc. Stock Price, News & Analysis

Vir Biotechnology announced that Dr. Phil Pang, its Chief Medical Officer, will participate in a fireside chat during the 22^nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 12:00 p.m. PT / 3:00 p.m. ET.

Investors can access a live webcast of the presentation in the Investors section of the Vir website, which will also be archived for 30 days.

Vir Biotechnology is dedicated to treating and preventing serious infectious diseases by leveraging innovative technologies and immunologic insights. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.

Vir Biotechnology announced that Phil Pang, M.D., Ph.D., Executive Vice President and Chief Medical Officer, will present at the Barclays Global Healthcare Conference on March 15, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of this presentation will be available on their website under the Events & Presentations section and archived for 30 days.

Vir Biotechnology is a commercial-stage immunology company focused on treating and preventing serious infectious diseases through innovative technology platforms. Their pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.

Vir Biotechnology has announced that Bolyn Hubby, Ph.D., the Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel about infectious diseases at the Cowen 43rd Annual Health Care Conference. This event is scheduled for March 7, 2023, at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast of the panel will be available on the Vir website under the Events & Presentations section and will remain accessible for 30 days.

Vir Biotechnology focuses on innovative solutions to treat serious infectious diseases through advanced immunological technologies. Its development pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.

Vir Biotechnology reported a significant year in 2022, recognizing $1.5 billion in collaboration revenue from sotrovimab. The company has a robust financial position with approximately $2.4 billion in cash and investments, allowing it to fund ongoing clinical trials in hepatitis B, hepatitis D, and influenza. Notable leadership transitions were announced, including the retirement of CEO George Scangos, effective April 3, 2023, and the appointment of Marianne De Backer as his successor. The company anticipates critical Phase 2 trial data and continues to progress in addressing COVID-19 and other infectious diseases.

Vir Biotechnology announced positive final draft guidance from the UK's NICE recommending the use of sotrovimab, a monoclonal antibody for COVID-19 treatment in adults at increased risk for severe disease.

This recommendation applies to patients who do not require supplemental oxygen and where alternatives like nirmatrelvir/ritonavir (Paxlovid) are unsuitable. Despite the positive guidance, no significant additional sales of sotrovimab in the UK are expected in 2023 due to existing inventory. Sotrovimab has received authorizations in over 40 countries but is not approved in the US.

Vir Biotechnology, a commercial-stage immunology company, announced it will provide a corporate update and report financial results for Q4 and full year 2022 on February 23, 2023. The financial results will be accessible via a press release after market close and can be found in the Investors section of their website.

Vir focuses on serious infectious diseases utilizing advanced immunologic technologies. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.

Vir Biotechnology has appointed Sung Lee as its new Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. He takes over from Howard Horn, who will remain in an advisory role during the transition. Lee brings over 20 years of experience in financial leadership, having held senior positions at companies like Gilead Sciences and most recently served as CFO at MorphoSys AG.

The company's CEO, George Scangos, expressed confidence in Lee’s ability to drive growth and strengthen financial performance. Horn, a key figure in Vir's early development, highlighted the company's strong financial foundation as he departs.